SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

NCT05435742 | Terminated Phase 1 DMC

• 1 other identifier: SB211
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

The study will be conducted in adult patients with Chemotherapy-induced Peripheral Neuropathy (CIPN) that has been persistent for at least 3 months following completion of chemotherapy. A total of 60 patients will be enrolled in equal numbers of a placebo group and two different SON-080 dose groups. Treatment period will be 12 weeks long and patients will be followed-up for an additional 12 weeks.

Conditions

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Outcome Measures

Primary Outcomes (1)

• Evaluate the safety of SON-080

  Frequency and severity of treatment emergent adverse events (TEAEs), including serious adverse events (SAEs) and deaths, by treatment. Note that progression of, or death from, the underlying tumor will not be considered an SAE.

  Through study completion, an average of 24 weeks

Secondary Outcomes (3)

• Evaluate the pharmacokinetics of SON-080

  Through study completion, an average of 24 weeks

• Evaluate the immunogenicity of SON-080

  Through study completion, an average of 24 weeks

• Evaluate the preliminary efficacy of SON-080

  Weeks 5, 9, and 12 of treatment, as well as 4 and 12 weeks after the end of treatment.

Study Arms (3)

SON-080 Dose Level 1

EXPERIMENTAL

20 µg SON-080 SC administration TIW

Biological: SON-080

SON-080 Dose Level 2

EXPERIMENTAL

60 µg SON-080 SC administration TIW

Biological: SON-080

Matching Placebo

PLACEBO COMPARATOR

Matching placebo 20 µg SON-080 SC administration TIW

Biological: SON-080

Interventions

SON-080 BIOLOGICAL

Recombinant human interleukin-6 (rhIL-6)

Matching Placebo; SON-080 Dose Level 1; SON-080 Dose Level 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years, inclusive, at the time of Screening.
• Have persistent CIPN at 3 months or more after chemotherapeutic treatment arrest (QLQ-CIPN20 score of 30 to 100).
• Have a history of cancer that is stable or in remission at the time of study entry.
• Have a history of treatment with a chemotherapeutic agent in the taxane, organoplatin, or vinca alkaloid family.
• Must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 at Screening.
• Must have adequate organ function, defined as:
• Hematologic function defined as National Cancer Institute (NCI) CTCAE Grade 1 or less for all blood parameters.
• Renal function defined as calculated creatinine clearance or radioisotope glomerular filtration rate \>60 mL/min/1.73 m2 or normal serum creatinine with a maximum serum creatinine of 1.7 mg/dL for males and 1.4 mg/dL for females.
• Hepatic Function defined as:
• Alanine aminotransferase (ALT) ≤3 × the upper limit of normal (ULN) for age.
• Total bilirubin ≤1.5 × ULN (unless the patient has Grade 1 bilirubin elevation due to Gilbert's disease or a similar syndrome involving slow conjugation of bilirubin).
• Either the patient or the caregiver must be willing and able to administer SC treatment in an at-home setting after training.
• Female patients of childbearing potential who are not currently pregnant or lactating must have a negative serum pregnancy test (beta-human chorionic gonadotropin \[β HCG\]) on day 1 and agree to abstinence or use a highly effective method of birth control for 30 days before the study, during the study, and for 30 days after the last dose of study intervention. Females who are not of childbearing potential (have had a tubal ligation, hysterectomy, or bilateral oophorectomy, or are ≥ 1-year postmenopause) or have a partner who has had a vasectomy do not need to use any contraception.
• Nonchildbearing potential is defined as surgically sterile (documented hysterectomy, tubal ligation, or bilateral salpingo-oophorectomy) or postmenopausal (defined as 12 months of spontaneous amenorrhea). If necessary, a follicle-stimulating hormone (FSH) level ≥ 35 IU/L at Screening will be considered confirmatory in the absence of a clear postmenopausal history. If a patient is not sexually active, but becomes active, then she and her male partner must use adequate contraception.
• Male patients and their female partners must agree to use adequate contraception (including a barrier method) during the study and for 30 days after the last dose of SON-080. Contraception guidance is described in the protocol.

You may not qualify if:

• Evidence of current alcohol or drug dependence.
• Evidence for other cause of chemotherapeutic neuropathy, e.g., use of colchicine, amiodarone, thalidomide, vitamin B12 deficiency, etc.
• Active infection with SARS-CoV-2, as determined by local SOPs for testing during Screening.
• History of hepatic disease or active clinically significant liver function test results, defined as chronically abnormal ALT, aspartate aminotransferase (AST), total bilirubin and fractionated bilirubin, and alkaline phosphatase \>1.5 × the ULN. Note: Isolated bilirubin \>1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%.
• Diagnosis of or positive screening result for hepatitis B surface antigen (HbsAg), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus (HIV)-1 or HIV-2.
• Known allergies to any of the ingredients of the medicinal product or to acetaminophen.
• History of brain metastases.
• Diagnosed with lymphoma, Kaposi's sarcoma, or multiple myeloma.
• Significant unstable vascular disease, as judged by the Investigator.
• Any other investigational drug in the 4 weeks preceding treatment administration. Note: COVID-19 vaccines will be allowed if administered more than 14 days before the first dose administration.
• Clinical history of a thrombosis, deep vein thrombosis, or pulmonary embolus in the past year.
• History of any active infection within 14 days before the first dose of SON-080, if deemed clinically significant by the Investigator and Sponsor.
• Concurrent conditions that could interfere with safety and/or tolerability measurements.
• Pregnant and/or lactating.
• Unable or unwilling to cooperate with the Investigator for any reason.

Sponsors & Collaborators

• Sonnet BioTherapeutics: lead

Study Sites (1)

Emeritis Research

Camberwell, Victoria, 3124, Australia

Location

Related Publications (1)

• de Baat A, Trinh B, Ellingsgaard H, Donath MY. Physiological role of cytokines in the regulation of mammalian metabolism. Trends Immunol. 2023 Aug;44(8):613-627. doi: 10.1016/j.it.2023.06.002. Epub 2023 Jul 7.

  PMID: 37423882 DERIVED

Study Officials

• Richard Kenney, MD

  Sonnet BioTherapeutics

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 14, 2022
• First Posted: June 28, 2022
• Study Start: October 27, 2022
• Primary Completion: March 17, 2024
• Study Completion: March 17, 2024
• Last Updated: April 12, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)